Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.48 |
| ▸ | GPR88 | Q9GZN0 | 10/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902977 | 1.00 | KDM4E (0.51) | KDM4ECASP1HSD17B10NPEPPSGPR88 | |
| SCHEMBL14059266 | 1.00 | KDM4E (0.51) | KDM4ECASP1HSD17B10NPEPPSGPR88 | |
| SCHEMBL902409 | 1.00 | KDM4E (0.51) | KDM4ECASP1HSD17B10NPEPPSGPR88 | |
| SCHEMBL901429 | 1.00 | KDM4E (0.51) | KDM4ECASP1HSD17B10NPEPPSGPR88 | |
| SCHEMBL7214698 | 0.84 | MAPT (0.51) | KDM4ECASP1HSD17B10NPEPPSMAPT | |
| SCHEMBL7214703 | 0.84 | MAPT (0.51) | KDM4ECASP1HSD17B10NPEPPSMAPT | |
| SCHEMBL7214700 | 0.84 | MAPT (0.51) | KDM4ECASP1HSD17B10NPEPPSMAPT | |
| SCHEMBL18706738 | 0.84 | ITK (0.51) | KDM4ECASP1HSD17B10GPR88ITK | |
| SCHEMBL15797898 | 0.82 | NOS3 (0.43) | KDM4ECASP1HSD17B10MAPTPKM | |
| SCHEMBL15805100 | 0.82 | NOS3 (0.43) | KDM4ECASP1HSD17B10MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621926-B1 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2748151-B1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2016-03-16 | — | — | EP | disclosed |
| US-9062059-B2 | Pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062059-B2 | Pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-8975261-B2 | Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975261-B2 | Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8957077-B2 | Pyrazolopyrimidine PDE 10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957077-B2 | Pyrazolopyrimidine PDE 10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20140336195-A1 | ARYLOXMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-11-13 | — | — | US | disclosed |
| US-20140336195-A1 | ARYLOXMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-11-13 | — | — | US | disclosed |
| US-20140228368-A1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20140228368-A1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | disclosed |
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| WO-2013028590-A1 | PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012162213-A1 | ARYLOXYMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012044562-A2 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | PDE12, PDE5A, PDE4A | KDM4E 1478/4885CASP1 3033/4885HSD17B10 125/4885 |
| US-20140228368-A1 | PYRIMIDINE PDE10 INHIBITORS | PDE12, PDE10A, PDE11A | KDM4E 2308/4885CASP1 3438/4885HSD17B10 296/4885 |
| US-20140336195-A1 | ARYLOXMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS | PDE10A, PDE12, PDE4A | KDM4E 1157/4885CASP1 3079/4885HSD17B10 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.